Serious Cardiovascular Adverse Event Associated with Hydroxychloroquine with Azithromycin in Patient with COVID-19 : A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)

Lomesh Jibhau Khairnar; Vijay Pawar

doi:10.36948/ijfmr.2022.v04i06.1012

Serious Cardiovascular Adverse Event Associated with Hydroxychloroquine with Azithromycin in Patient with COVID-19 : A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)

Author(s)	Lomesh Jibhau Khairnar, Vijay Pawar
Country	India
Abstract	The use of Hydroxychloroquine combine with Azythromycin for the treatment of coronavirus disease (COVID-19) it may increases the risk of serious cardiovascular advere events. WHO not recommended for the use of HCQ to treat the COVID-19 because it has serious side effect on heart like Arrhythmia ,cardiac toxicity. In the following describe the risk of serious cardiovascular adverse event using HCQ is combined with Azythromycin it compared with that therapeutic alternatives. Some clinical trial that reporting the combine of HCQ with AZ demonstrated better efficacy than signal drug combination of HCQ and AZ has synergestic effect against viral infectious. The FAERS that evaluate adverse effect reports ,medication error reports and product quality complaint resulting in adverse effect that were submitted to FDA. The performing the test to analysis to case series using the US FDA Adverse Event Reporting System(FAERS).
Keywords	COVID-19, Hydroxychloroquine, Azythromycin, Cardiovascular Risks
Field	Medical / Pharmacy
Published In	Volume 4, Issue 6, November-December 2022
Published On	2022-11-22
Cite This	Serious Cardiovascular Adverse Event Associated with Hydroxychloroquine with Azithromycin in Patient with COVID-19 : A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) - Lomesh Jibhau Khairnar, Vijay Pawar - IJFMR Volume 4, Issue 6, November-December 2022. DOI 10.36948/ijfmr.2022.v04i06.1012
DOI	https://doi.org/10.36948/ijfmr.2022.v04i06.1012
Short DOI	https://doi.org/grb6bk

View / Download PDF File

E-ISSN 2582-2160

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 4 Cover Page Vol 6 Isu 3 Cover Page Vol 6 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-5948-55	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Serious Cardiovascular Adverse Event Associated with Hydroxychloroquine with Azithromycin in Patient with COVID-19 : A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)

Share this